Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.

  title={Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.},
  author={Maurizio Zangari and Eric Siegel and Bart Barlogie and Elias Anaissie and Fariba Saghafifar and Athanasios Fassas and Christopher L Morris and Louis Fink and Guido Tricot},
  volume={100 4},
Ten percent of newly diagnosed myeloma patients treated with any type of chemotherapy develop deep venous thrombosis (DVT). Thalidomide has proven activity in refractory multiple myeloma (MM), and although single-agent thalidomide has minimal prothrombogenic activity, its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT. We analyzed the incidence of DVT in 232 MM patients who received a combination of chemotherapy and thalidomide on 2 protocols… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 75 extracted citations


Publications referenced by this paper.
Showing 1-10 of 23 references

A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer [abstract

  • P Rosen, R Amado, J Hecht
  • ASCO. 2000;19:5D
  • 2002

A phase II trial of weekly intravenous gemcitabine (G) with prolonged continuous infusion 5-fluorouracil (F) and oral thalidomide (T) in patients with metastatic renal cell cancer [abstract

  • AA Desai, NJ Vogelzang, B Rini, C Ryan, M Rodriguez, WM. Stadler
  • ASCO
  • 2001

Phase II trial of thalidomide and BCNU in recurrent high-grade gliomas [abstract

  • HA Fine, EA Maher, PY Wen, T Batchelor, E Viscosi, W. Figg
  • ASCO
  • 2001

Dose finding study of cisplatin, gemcitabine and SU5416 in patients with advanced malignancies [abstract

  • G Giaccone, L Rosen, B Kuenen
  • Clin Cancer Res
  • 2000

Chemoangiotherapy with DT-PACE for previously treated multiple myeloma (MM) [abstract

  • N Munshi, R Desikan, M Zangari
  • 1999

Similar Papers

Loading similar papers…